Two Sigma Advisers LP Has $1.91 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Two Sigma Advisers LP cut its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,300 shares of the company's stock after selling 23,200 shares during the quarter. Two Sigma Advisers LP owned approximately 0.08% of NewAmsterdam Pharma worth $1,910,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of NAMS. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $80,000. KLP Kapitalforvaltning AS bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $154,000. The Manufacturers Life Insurance Company bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $221,000. Finally, Keybank National Association OH bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $257,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank increased their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC reduced their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Trading Down 1.2%

NASDAQ:NAMS traded down $0.22 during mid-day trading on Tuesday, hitting $18.71. The company's stock had a trading volume of 39,693 shares, compared to its average volume of 644,222. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -9.95 and a beta of 0.01. The stock has a fifty day moving average of $17.89 and a 200-day moving average of $20.93.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. On average, equities analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This represents a 0.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.